top of page
Data STACK-01.png

Data & Analytics Highlighting Industry Stats, Trends, Analogs, Company Profiles, and Key Insights

Pipeline & Launch Analytics
Legal Analytics
Pricing, Access, Rebate, & Sales Analytics

IPD's Data STACK subscriptions support decision-making with curated datasets and visualizations, expert analytics, easy-to-use analog generators, and trend reports in these impactful coverage areas:

  • Brand pipeline and launch analytics

    • Clinical development​

    • Brand drug approvals

  • Generic filing and launch analytics

    • Generic pipeline and launches​

    • ANDA filing and timing

    • Authorized generics

    • Generic launch analogs and competitive intelligence

  • Litigation filing analytics

  • Settlement analytics

  • Litigation outcome analytics

  • Litigation decision timing analytics

  • Sales and rebate analytics

  • Therapy cost analytics

  • Hospital price transparency analytics

  • Formulary analytics

  • Limited distribution analytics

Explore Recent Reports

March 2025

DATA STACK Trend Report: January 2025 Drug Price Changes

IPD’s latest DATA STACK Trend Report shows that, among single-source brand drugs that had price increases in January 2025, most had increases of 2%-4%. This marks a shift downward from the 4%–6% range observed in 2023 and 2024. Additionally, over 83% of price increases in January 2025 remained at or below 6%, reflecting a trend of stabilization compared to previous years. Read the report to find out more: https://www.ipdanalytics.com/sample-reports

Read All

November 2024

An Examination of Factors that Influence Patent Exclusivity Retention of Brand Drugs

IPD has released a new Data STACK Trend Report: “An Examination of Factors that Influence Patent Exclusivity Retention of Brand Drugs.”

In this report, we analyzed 141 brand drugs across 40 manufacturers that either: (1) faced first-time generic entry from January 2018 through June 2024, (2) lacked generic competition as of June 2024 despite having no unexpired patents or exclusivity remaining, or (3) whose manufacturer launched an early authorized generic through an out-licensing agreement or in-house during the review period. The report reveals trends such as longer exclusivity retention for high-complexity drugs, the relationship between gross sales and retained exclusivity, and how brand manufacturers leverage composition-of-matter and formulation patents to extend protection.

Read All
bottom of page